Speaker Profile
M.D., Ph.D., Professor of Medicine (Oncology); C.M.A, Stanford
Biography
Ash A. Alizadeh, MD, PhD is the Moghadam Family Professor of Medicine at Stanford University and a practicing hematooncologist and physician-scientist in the Division of Oncology, leading the Cancer Genomics program for the Stanford Cancer Institute. His research focuses on the development of data-driven approaches to better understand cancer biology, improve diagnostics, and personalize therapies. Dr. Alizadeh is a recognized leader in computational methods for cancer biology and oncology translational research, contributing extensively to the advancement of precision medicine. His group has contributed to the development of several commonly used liquid biopsy techniques for cancer detection and monitoring (including CAPP-Seq, PhasED-Seq, RARE-Seq, EPIC-Seq), as well as methods for tumor immune profiling (including CIBERSORT and EcoTyper).
Talk
Non-Clinical Services Showcase:
Future Cancer Care Today
Session Abstract – PMWC 2027 Silicon Valley
Track Chair:
Victor Velculescu, Johns Hopkins
PMWC Award Ceremony
• Rebecca Fitzgerald, University of Cambridge (Luminary)
• Mary-Claire King, University of Washington (Pioneer)
• Nickolas Papadopoulos, Johns Hopkins (Pioneer)
Featured Speakers
• Mary-Claire King, University of Washington
• Rebecca Fitzgerald, University of Cambridge
• Nickolas Papadopoulos, Johns Hopkins
• Victor Velculescu, Johns Hopkins
• Phil Castle, NIH
• Elad Ziv, UCSF
• Ash Alizadeh, Stanford
• Hamed Amini, Hepta
• Becky Taub, Madrigal Pharmaceuticals
• Trevor Pugh, University of Toronto
• Doga Gulhan, Harvard
• Pranav Rajpurkar, Harvard
• Chris Douville, Johns Hopkins
• Sylvia Katina Plevritis, UCSF
In Precision Medicine, Almost All Diseases Are Genetically Rare
A genetics-first keynote framing risk, prevention, and actionability.
The Reckoning
What the first wave of early detection got right and wrong.
The End of One Size Fits All
Risk-stratified screening, high-risk populations, and single-cancer tests.
Treating Disease at the Earliest Stage
Where detection and therapeutic interception begin to converge.
Pre-Cancer Detection & the Liver Disease Frontier
cfDNA and clinical action across the liver-disease-to-cancer continuum.
AI Across Multimodal Signals
Fragmentomics, methylation, imaging, pathology, and integration: hype versus real science.
PMWC Hall of Impact
Previous Speakers Include
Nobel laureates, technology founders, regulators, CEOs and scientific pioneers who have taken the PMWC stage.
